SAN FRANCISCO & LONDON–(Business WIRE)–Feb 11, 2021–
SR A person, a trans-Atlantic enterprise capital company investing in lifestyle sciences businesses, declared nowadays that Chris Chai and Peter Van Vlasselaer, Ph.D. have joined the business as Venture Companions. Both equally men and women have strong track records in the development and evolution of early-stage biotechnology corporations, with an emphasis on drug progress, fundraising, and operations.
“Chris and Peter carry an remarkable depth of monetary and drug-searching expertise to our group. As we shift ahead to construct on our newly impartial fund and portfolio of emerging everyday living sciences businesses, their insight, standpoint, and experience will increase to the know-how by now resident in our trans-Atlantic group,” mentioned Simeon J. George, M.D., SR A single Main Executive Officer.
“Chris and Peter have long-standing interactions with the company, getting held senior management positions in prosperous SR A person portfolio corporations. They convey confirmed keep track of documents as well as a demonstrated capacity to develop hugely productive working relationships with scientific founders, fellow management and other vital stakeholders,” Dr. George added.
Chris Chai, Enterprise Husband or wife, Cash Marketplaces
Chris will come to SR One particular from Principia Biopharma in which, as Chief Financial Officer for 7 a long time, he guided the firm from an early-stage personal venture-backed corporation to the public marketplaces and, in the long run, by way of to its acquisition by Sanofi for $3.7 billion in September 2020. SR One was an early Sequence A investor in Principia, and remained associated at the Board degree all the way as a result of to the acquisition. Chris will focus on building and executing financing procedures for portfolio firms, in particular all those advancing from the late-stage private arena in the direction of the community funds markets and outside of. Importantly, his background of about 20 yrs in govt administration at biotech companies and financial investment banking consists of a mix of functioning CFO and finance management roles at Principia, MAP Prescription drugs and CV Therapeutics, as properly as at the bulge-bracket bank, J.P. Morgan. He has a Bachelor’s diploma in Functions Study and Industrial Engineering from Cornell University.
Peter Van Vlasselaer, Ph.D., Enterprise Partner
Peter brings to SR A single above 25 years of working experience in the biotech marketplace, which includes CEO and/or Executive Chairman roles at SR A person portfolio corporations Real North Therapeutics, which he co-started and was acquired in 2017 by Bioverativ (now portion of Sanofi), and iPierian, obtained in 2014 by Bristol Myers Squibb. He will function with SR A person to launch new businesses as nicely as to critique investment possibilities. Most not too long ago, Peter was the Founder, President, and CEO of ARMO Biosciences, a organization he led through to its acquisition by Eli Lilly in 2018 for $1.6 billion, shortly just after its IPO. Prior to that, Peter launched and held CEO positions at ARRESTO and AVIDIA, the place he led the providers to their acquisition by Gilead and AMGEN, respectively. He has also held govt positions at InterMune and Dendreon. Peter currently serves on the Boards of Amphivena, in which he is Executive Chair, Asceneuron (an SR A person portfolio firm) the place he is the Chair, and RGENIX. He has a diploma in Zoology and a Ph.D. in Immunology from the University of Leuven, Belgium. He was Postdoctoral Fellow at the Division of Rheumatology at the Stanford College Clinical School and DNAX Analysis Institute. He has authored many peer-reviewed scientific publications and guide chapters, and he is an inventor on multiple patents.
SR One Funds Administration is a top trans-Atlantic biotech enterprise capital agency that companions with prime business people, experts, and financial commitment companions to request to develop elite biotechnology firms. Our mission is to translate ground-breaking systems into following generation medicines to profit patients with major unmet clinical wants. The business in 2020 was spun out of GSK wherever it was founded in 1985, and has a existence in San Francisco, CA, Philadelphia, PA, and London, British isles. For a lot more details, please visit www.srone.com.
Search phrase: CALIFORNIA EUROPE UNITED STATES UNITED KINGDOM NORTH The usa
Business Keyword: FINANCE Professional Expert services BIOTECHNOLOGY Health and fitness PHARMACEUTICAL Basic Health and fitness OTHER SCIENCE SCIENCE ONCOLOGY
Copyright Business Wire 2021.
PUB: 02/11/2021 07:00 AM/DISC: 02/11/2021 07:01 AM
Copyright Organization Wire 2021.
